Articles by Elizabeth Swanson, MD
When to Change Therapy for Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD A brief discussion on when it is best to switch therapy while treating patients for atopic dermatitis.
Atopic Dermatitis: Systemic Therapy Armamentarium
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Shared insight on the armamentarium of systemic agents available to treat atopic dermatitis.
Topical Calcineurin and PDE-4 Inhibitors in the Treatment of AD
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD A review of topical therapies that have been long utilized for patients with atopic dermatitis.
Atopic Dermatitis: Patient Factors in Selecting Therapy
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD A brief review of patient and disease factors that inform selection of therapy for atopic dermatitis.
Nonpharmacological Approaches to Managing Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Expert insight on nonpharmacological strategies to treat atopic dermatitis and improve patient quality of life.
Concomitant Use of JAK Inhibitors in Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD A brief evaluation of the concomitant use of JAK inhibitors, topical or systemic, in patients with atopic dermatitis.
Systemic JAK Inhibition in Atopic Dermatitis Care Strategies
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Switching its focus to systemic JAK inhibitors, the panel reviews real-world use of available agents to treat patients with atopic dermatitis.
Topical JAK Inhibition in Atopic Dermatitis Care Strategies
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD The panelists discuss real-world use of topical ruxolitinib in atopic dermatitis management given safety, efficacy, and availability.
Atopic Dermatitis: Clinical Trials With Topical Ruxolitinib
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Considerations for topical ruxolitinib with deference to positive clinical trial results in atopic dermatitis.
An Overview of JAK Inhibition in Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Shared insight on the available JAK inhibitors for atopic dermatitis, both topical and systemic.
Identifying Comorbidities Associated With Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Experts reflect on the various comorbid conditions associated with atopic dermatitis and how they can affect patients.
What is the Burden of Atopic Dermatitis?
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Comprehensive discussion on how atopic dermatitis can impact a patient’s quality of life.
Persistent Atopic Dermatitis and Flare-ups
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Considerations for persistent atopic dermatitis vs outgrowing disease, followed by triggers that can result in flare-ups.
Understanding Patient Presentations With Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD Shared insight on the ways a child or adult may present with atopic dermatitis.
The Pathophysiology of Atopic Dermatitis
ByLawrence Eichenfield, MD,Raj Chovatiya, MD, PhD,Leon Kircik, MD,Peter Lio, MD ,Elizabeth Swanson, MD A panel of experts review the pathophysiology of atopic dermatitis and its contributing factors.
